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■ Abstract
Background: Interleukin (IL) 13 is a key cytokine in asthma, regulating fi brosis, airway remodeling, induction of immunoglobulin E synthesis 
by B cells, bronchial hyperresponsiveness, and mucus production. IL-13 signals through the type II IL-4 receptor (IL-4R), which is composed 
of the IL-4Rα and the IL-13Rα1 chains. Another IL-13 binding chain, IL-13Rα2, binds IL-13 with high affi nity but has no known signaling 
capability and is thought to serve as a decoy receptor providing tight regulation of IL-13 responses. 
Methods: In this study, we investigated the cellular localization of IL-13Rα2 in human primary bronchial epithelial cells and fi broblasts 
using fl ow cytometry and confocal microscopy, as well as the in vivo expression of IL-13Rα2 in the human bronchial mucosa by means 
of immunohistochemistry. 
Results: IL-13Rα2 is predominantly an intracellular rather than a membrane-bound molecule in both human primary bronchial epithelial cells 
and fi broblasts and displays a diffuse granular cytoplasmic distribution in both cell types. IL-13Rα2 protein is expressed in vivo in the human 
bronchial mucosa with its expression being higher in bronchial epithelial cells than bronchial fi broblasts both in vivo and in vitro. 
Conclusions: IL-13Rα2 is expressed by both human primary bronchial epithelial cells and fi broblasts as an intracellular protein with a diffuse 
cytoplasmic distribution. In vivo, IL-13Rα2 is expressed in the human airway mucosa mainly by bronchial epithelial cells. 
Key words: IL-13 receptor α2. Intracellular protein. Cellular localization. Cytoplasmic compartment. Bronchial epithelial cells. Bronchial 
fi broblasts.
■ Resumen
Antecedentes: La interleucina (IL) 13 es una citocina que tiene un papel clave en el asma, ya que regula la fi brosis, la modifi cación de las 
vías respiratorias, la inducción de la síntesis de inmunoglobulina E mediante los linfocitos B, la hiperreactividad bronquial y la producción 
de mucosidad.  La IL-13 transmite señales a través del receptor IL-4 de tipo II (IL-4R) que consta de las cadenas IL-4Rα e IL-13Rα1. Otra 
cadena de unión de IL-13, la IL-13Rα2, une la IL-13 con una gran afi nidad pero no se conoce que tenga ninguna capacidad de transmitir 
señales y se cree que actúa como un receptor señuelo, proporcionando una rigurosa regulación de las respuestas de la IL-13.
Métodos: En este estudio, se investigó la localización celular de la IL-13Rα2 en células epiteliales bronquiales primarias humanas y en 
los fi broblastos, a través de la citometría de fl ujo y la microscopia confocal, así como también la expresión de la IL-13Rα2 in vivo en la 
mucosa bronquial humana, por medios inmunohistoquímicos.
Resultados: La IL-13Rα2 es una molécula predominantemente intracelular y no de superfi cie, ya sea en células epiteliales bronquiales 
primarias humanas, como en fi broblastos, y presenta una distribución citoplasmática granular difusa en ambos tipos de célula. La proteína 
IL-13R α2 se expresa in vivo en la mucosa bronquial humana y su expresión es más elevada en las células epiteliales bronquiales que en 
los fi broblastos bronquiales, ya sea in vivo o in vitro.
Conclusiones: La IL-13Rα2 se expresa mediante células epiteliales bronquiales primarias humanas y fi broblastos como una proteína 
intracelular con una distribución citoplasmática difusa. La IL-13Rα2 in vivo se expresa en la mucosa de las vías respiratorias principalmente 
mediante las células epiteliales bronquiales.
Palabras clave: Receptor α2 de IL-13. Proteína intracelular. Localización celular. Compartimiento citoplasmático. Células epiteliales 
bronquiales. Fibroblastos bronquiales.
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Introduction
Interleukin (IL) 13 plays a key role as an effector molecule 
in asthma through many mechanisms including induction 
of immunoglobulin (Ig) E synthesis by B cells [1], airway 
hyperresponsiveness [2], airway eosinophilia [3], mucus 
production [4], and airway remodeling [5,6]. IL-13 exerts 
its activity via its receptor complex, which consists of the 
heterodimeric proteins IL-13Rα1 and IL-4Rα [7]. The IL-
13Rα1/IL-4Rα heterodimer also serves as an alternative 
receptor for IL-4, especially in nonhematopoietic cells that do 
not express the common gamma chain (IL-2Rγ) [8]. Another 
receptor chain, IL-13Rα2, binds IL-13 with high affi nity (Kd 
of approximately 250 pM) [9]. 
IL-13Rα2 has no known signaling capability and its short 
cytoplasmic domain of 17 amino acids does not contain the 
conserved box-1 region that is critical for downstream signal 
transduction [10]. IL-13Rα2 is thought to be a decoy receptor 
or a dominant negative inhibitor that provides tight regulation 
of IL-13 responses without affecting IL-4 signaling [11]. 
This hypothesis has been supported by Kawakami and co-
workers [12], who found that transfection of Chinese hamster 
ovary cells (CHO-K1) with IL-13Rα1 and IL-4Rα induced 
STAT6 phosphorylation, whereas co-transfection with the 
IL-13Rα2 chain abolished STAT6 activation. Similarly, 
overexpression of IL-13Rα2 in renal carcinoma cell lines 
reduced their ability to respond to IL-13 [13], while the 
pro-B cell line Ba/F3 expressing IL-13Rα2 was unable to 
proliferate in response to IL-13 [14]. IL-13Rα2 can also inhibit 
IL-13 activities through other mechanisms. For instance, in 
the glioblastoma cell line 293T, transient expression of IL-
13Rα2 inhibited IL-13 and IL-4-mediated STAT6 activation, 
possibly through the physical interaction of the IL-13Rα2 
protein and the IL-4Rα chain [15]. In vivo studies have also 
highlighted the role of IL-13Rα2 in the inhibition of IL-
13-mediated responses. IL-13Rα2-defi cient mice displayed 
enhanced macrophage development and IgE production [16], 
and Schistosoma mansoni-infected IL-13Rα2-defi cient mice 
showed a marked exacerbation in hepatic fi brosis compared 
to wild-type mice [17]. However, recently, an alternative 
explanation for the actions of IL-13Rα2 has been put forward 
in which it is suggested that in fact signaling through IL-
13Rα2 in macrophages results in the activation of an AP-1 
variant containing c-jun and Fra-2 and consequent production 
of transforming growth factor ß in a model of murine lung 
fi brosis [18]. These apparently confl icting roles for IL-13Rα2 
remain to be reconciled. IL-13Rα2 has a more restricted pattern 
of expression when compared to that of IL-13Rα1 and was 
found to be expressed in fi broblasts, airway smooth muscle 
cells, and airway epithelial cells [19].
Although IL-13Rα2 is predicted to be a membrane-bound 
protein, in fact, it has been shown by fl ow cytometry to be 
predominantly an intracellular molecule in various human 
cell types including monocytes and nasal epithelial cells [20], 
airway fi broblasts [21], and bronchial epithelial cells [22]. 
It has previously been reported that A549 cells and human 
primary nasal epithelial cells exhibited diffuse cytoplasmic 
IL-13Rα2 expression when cells were visualized under 
confocal microscopy [20]. However, the cellular localization 
of IL-13Rα2 in human primary bronchial epithelial cells and 
fi broblasts has not been described, and its in vivo expression in 
the human airways has not been reported. The purpose of this 
study was to investigate the cellular localization of IL-13Rα2 
in human primary bronchial epithelial cells and fi broblasts, 
and to assess the pattern of IL-13Rα2 expression in the human 
bronchial mucosa. 
Materials and Methods
Cells and Reagents
Primary bronchial epithelial cells and primary bronchial 
fi broblasts were established from bronchial brushings and 
bronchial biopsies, respectively, as previously described [6,23]. 
Cells were obtained by fi beroptic bronchoscopy from 3 mild 
asthmatic subjects with a mean age of 32 years and mean forced 
expiratory volume in 1 second (FEV
1
) of 86% (range, 72% 
– 98%), all receiving inhaled ß
2
-agonists only (salbutamol). 
Primary airway epithelial cells were cultured at 37ºC, 5% CO
2
, 
in bronchial epithelium growth medium (BEGM; Clonetics, San 
Diego, California, USA) supplemented with 50 IU/mL penicillin 
(Sigma-Aldrich, Poole, UK), and 50 µg/mL streptomycin 
(Sigma-Aldrich) in collagen-coated tissue culture fl asks. When 
confl uent, the cells were passaged using trypsin (Sigma-Aldrich) 
and were allowed to further expand until used for assays at 
passage 3. Primary bronchial fibroblasts were maintained 
in Dulbecco’s modifi ed Eagle’s medium (DMEM; GIBCO 
Invitrogen, Paisley, UK) containing 10% heat-inactivated 
fetal calf serum (FCS) (Sigma-Aldrich), 2 mM L-glutamine 
(Biowhittaker, Wokingham, UK), 50 IU/mL penicillin, and 
50 µg/mL streptomycin. Cells were used for experimentation 
between passages 5 to 8. A549 lung adenocarcinoma (American 
Type Culture Collection, ATCC) and 16HBE human bronchial 
epithelial cell lines were grown in DMEM containing 10% heat-
inactivated FCS, 50 IU/mL penicillin, 50 µg/mL streptomycin, 
and 2 mM L-glutamine. NCI-H292 lung mucoepidermoid 
adenocarcinoma (ATCC) and U937 promyelomonocytic 
(ATCC) cell lines were maintained in RPMI 1640 (GIBCO 
Invitrogen) supplemented with 10% heat-inactivated FCS, 2 mM 
L-glutamine, 50 IU/mL penicillin, and 50 µg/mL streptomycin. 
The Jurkat T cell leukemia cell line (European Cell and Animal 
Culture Collection, Salisbury, UK) was cultured in RPMI 1640 
medium supplemented with 10% heat-inactivated FCS, 2 mM 
L-glutamine, and 50 µM ß-mercaptoethanol (Sigma-Aldrich). 
Reverse-Transcriptase Polymerase Chain Reaction
Total RNA was extracted from established primary cell 
cultures and cell lines using TRIzol (Life Technologies, Paisley, 
UK) and from whole blood (1.5 mL) using the RNeasy Blood 
Kit (Qiagen, Crawley, UK) according to the manufacturers’ 
instructions. Reverse transcription was performed for 1 hour at 
37ºC using 1 µg total RNA with 1 µM oligo(dT)15 as a primer 
and 4 U Omniscript reverse transcriptase (Qiagen) in the presence 
of 0.5 mM dNTPs, 10 U RNase inhibitor (Ambion, Austin, Texas, 
USA), in a total volume of 20 µL. Polymerase chain reaction (PCR) 
involved 2 µL cDNA template (from the 20 µL cDNA reaction), 
standard PCR buffer, 0.6 µM of each primer, 0.2 mM dNTPs, and 
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0.025 U/µL Jumpstart Taq DNA polymerase (Sigma-Aldrich) 
in a total volume of 25 µL using a TETRAD thermocycler (MJ 
Research, Boston, Massachusetts, USA). The following MgCl
2
 
concentrations and primers were used: IL-13Rα2 (amplicon size: 
426 base pairs) amplifi cation was performed with 2 mM MgCl
2
, 
forward 5’-GGA GCA TAC CTT TGG GAC CT-3’, and reverse 
5’-TTG GCC ATG ACT GGA AAC TG-3’; APRT (amplicon size: 
245 base pairs) amplifi cation was done with 1 mM MgCl
2
, forward 
5’-GCT GCG TGC TCA TCC GAA AG-3’, and reverse 5’-CCT 
TAA GCG AGG TCA GCT CC-3’. Thermal cycling included a 
single cycle at 95ºC for 5 minutes followed by 35 cycles at 94ºC 
for 30 seconds, annealing at 64ºC for IL-13Rα2 and 56ºC for 
APRT for 30 seconds, extension at 72ºC for 30 seconds, and fi nally 
a 72ºC soak for 10 minutes. Aliquots of PCR reactions were run 
on 2% agarose gels and visualized by ethidium bromide staining. 
All amplicons were designed to span introns and were tested to 
ensure they would not amplify genomic DNA. The specifi city of 
amplicons was confi rmed by direct sequencing using a BigDye 
Terminator version 3.0 (Applied Biosystems, Warrington, UK) 
with the products run on an ABI PRISM 377 DNA Sequencer 
(Applied Biosystems).
Flow Cytometry
Primary bronchial epithelial cells, primary bronchial 
fi broblasts, and airway epithelial cell lines were detached from 
fl asks using trypsin (Sigma-Aldrich). Cells were rinsed with 
phosphate-buffered saline (PBS) containing 0.1% sodium azide 
(Sigma-Aldrich) and resuspended in PBS containing 2% FCS 
at a concentration of 1  106 cells/mL. Then, 1  105 cells were 
incubated for 1 hour at 4ºC with a monoclonal anti-IL-13Rα2 
antibody (B-D13, Diaclone, Boldon, UK) in a fi nal antibody 
concentration of 2.5 µg/mL, then washed 3 times with PBS and 
resuspended in PBS containing a 1:50 dilution of fl uorescein 
isothiocyanate-conjugated goat anti-mouse IgG secondary 
antibody (Becton Dickinson, Oxford, UK) and 2% FCS. After 
incubation for 1 hour in the dark at 4ºC, cells were washed in 
cold PBS and then processed for analysis using a FACScan 
fl ow cytometer (Becton Dickinson). Data were analyzed using 
WinMDI 2.8 software. For intracellular staining, cells were 
fi xed in 1% paraformaldehyde and 0.2% saponin (both Sigma-
Aldrich), which was added to the antibody and wash solutions 
as permeabilization with saponin is reversible. The correct 
antibody dilutions for fl ow cytometry were established by 
titration. Isotype controls were used to confi rm specifi city and 
to enable subtraction of the background staining. Nonviable 
cells were excluded by the addition of 2.5 µg/mL propidium 
iodide (Sigma-Aldrich) in PBS.
Immunohistochemistry
Glycol methacrylate-embedded bronchial biopsies, obtained 
from 3 mild asthmatic subjects, were incubated with a monoclonal 
anti-IL-13Rα2 antibody (BD-13) for 1 hour at room temperature. 
Immunohistochemistry was performed using the avidin-biotin 
complex immunoperoxidase kit (Dako, Ely, Cambridgeshire, 
UK) according to the manufacturer’s instructions. Slides 
were developed using the liquid diamino benzidine substrate-
chromogen system (Dako) according to the manufacturer’s 
instructions and then lightly counterstained with hematoxylin. 
Confocal Microscopy 
Cells derived from 3 mild asthmatic subjects were grown on 
tissue culture collagen-coated slides, washed 3 times in cold PBS 
with 1% FCS and subsequently fi xed in 2% paraformaldehyde 
pH 7.4 for 15 minutes. Cells were incubated with a monoclonal 
anti-IL-13Rα2 antibody (B-D13) at a fi nal concentration of 
2.5 µg/mL for 1 hour in a solution containing PBS, 1% FCS, 
and 2% goat serum. Following PBS washes, an Alexa Fluor 
633-conjugated goat anti-mouse secondary antibody (Molecular 
Probes European BV, Leiden, The Netherlands) was added for 1 
hour. Coverslips were washed in PBS and counterstained with 
the nuclear dye SYTOX Orange (Molecular Probes European 
BV) (1µL in 1mL PBS) for 2 minutes. For permeabilized cells, 
0.2% saponin was added to the antibody solution and to all 
subsequent washes. After the fi nal wash, slides were covered 
with a coverslip and the edges sealed with nail polish. Cells were 
observed on a Leica SP2 confocal laser scanning microscope 
(Leica Microsystems, Heidelberg, Germany).
Ethical Approval
Ethical approval for this study was granted by the 
Southampton and South West Hampshire Joint Research Ethics 
Committee and written informed consent was obtained from 
all subjects undergoing bronchoscopy. 
Results
Expression of IL-13R2 in Airway Cells and Bronchial 
Mucosa
We initially established that IL-13Rα2 specifi c transcript 
is expressed in primary bronchial epithelial cells and primary 
bronchial fi broblasts (Figure 1). In addition, various airway 
epithelial cell lines including NCI-H292, A549, and 16HBE, as 
well as the promonocytic U937 cells also expressed IL-13Rα2 
mRNA. IL-13Rα2 transcript was not detected in Jurkat cells, 
whereas total blood leukocytes displayed only weak expression 
(Figure 1). We subsequently investigated the in vivo expression 
of IL-13Rα2 in bronchial biopsies derived from 3 mild 
asthmatic subjects. The columnar epithelial cells of the airway 
mucosa were the main sites of IL-13Rα2 immunoreactivity 
(Figure 2). Basal epithelial cells and fi broblasts displayed a 
weak staining pattern, while infi ltrating infl ammatory cells 
showed no positive staining.
IL-13Rα2 is an Intracellular Protein in Primary 
Bronchial Epithelial Cells and Primary Bronchial 
Fibroblasts
We evaluated the cell-surface expression of IL-13Rα2 
on primary bronchial epithelial cells, primary bronchial 
fi broblasts, various airway epithelial cell lines, and U937 cells 
by fl ow cytometry. We used a commercially available specifi c 
monoclonal mouse anti-human IL-13Rα2 antibody (B-D13) 
that recognizes epitopes of the extracellular domain of the 
protein. No cell-surface IL-13Rα2 expression was detected in 
any of the cell types examined (data not shown). In contrast, 
permeabilized cells exhibited strong intracellular expression 
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Figure 1.  mRNA expression of the interleukin 13 receptor α2 (IL-13Rα2). 
mRNA expression of IL-13Rα2 and adenosine phosphoribosyltransferase 
(APRT) was investigated by reverse-transcriptase polymerase chain 
reaction in primary bronchial epithelial cells (lane 2), U937 cells (lane 3), 
16HBE cells (lane 4), A549 cells (lane 5), NCI-H292 cells (lane 6), primary 
bronchial fi broblasts (lane 7), Jurkat cells (lane 8), and peripheral blood 
leukocytes (lane 9); lane 1 shows DNA size ladder. IL-13Rα2 is expressed 
by bronchial epithelial cells and fi broblasts, as well as airway epithelial 
cell lines. There is no IL-13Rα2 expression by Jurkat cells (lane 8), and 
only weak expression in U937 cells (lane 3) and white blood cells (lane 9). 
APRT was used as an internal positive control. Results are representative 
of 4 separate experiments. The number of cycles selected resulted in 
product being multiplied in the linear range of the reaction.
IL13RA2
APRT
1 2 3 4 5 6 7 8 9 A B
C D
Figure 2. Expression of IL-13Rα2 in the human bronchial mucosa. Bronchial 
biopsies were sectioned and stained for the presence of IL-13Rα2. The 
columnar epithelial cells show intense immunoreactivity, whereas basal 
epithelial cells exhibit a weaker staining pattern (C, D). No staining was 
seen in the control sections using an isotype-matched control antibody 
(A, B). Original magnifi cation, 40 (A, C) or 63 (B, D). Representative 
sections from biopsies of 3 mild asthmatic subjects are shown.
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Figure 3.  Intracellular stores of interleukin 13 receptor α2 (IL-13Rα2) in various cell types. U937 cells (A), A549 cells (B), NCI-H292 cells (C), primary bronchial 
fi broblasts (D), and primary bronchial epithelial cells (E) were permeabilized with saponin and stained with a specifi c monoclonal anti-IL-13Rα2 antibody. 
Fluorescence intensity by fl ow cytometry is represented by open histograms with a black line; red fi lled histograms correspond to background staining of 
isotype-matched controls. Representative histograms are shown in panels A-E. F, Mean channel fl uorescence (arbitrary units) in permeabilized cells stained for 
IL-13Rα2. Bars show the mean of 3 experiments; whiskers indicate SD. Statistical signifi cance was determined by t test.  Asterisk (*) indicates P = .008.
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of IL-13Rα2, suggesting that IL-13Rα2 is predominantly an 
intracellular protein (Figure 3). Expression of IL-13Rα2 in 
primary bronchial epithelial cells was approximately twice as 
high as in primary bronchial fi broblasts (Figure 3). We next 
examined whether the intracellular expression of IL-13Rα2, 
shown by fl ow cytometry, might be due to nonspecifi c binding 
of the antibody to intracellular proteins. We had previously 
shown by reverse-transcriptase PCR analysis that Jurkat cells 
do not express IL-13Rα2 mRNA, and would therefore not 
be expected to express IL-13Rα2 protein. Analysis of intact 
and permeabilized Jurkat cells by fl ow cytometry, using the 
monoclonal anti-IL-13Rα2 antibody (BD-13), revealed that 
Jurkat cells do not express either cell-surface or intracellular 
IL-13Rα2 protein (Figure 4), indicating that antibody binding 
in the intracellular compartment was specifi c.
Cellular Localization of IL-13Rα2
To identify the cellular localization of IL-13Rα2, we 
performed confocal laser scanning microscopy on both 
nonpermeabilized and saponin-permeabilized primary 
bronchial epithelial cells and primary bronchial fi broblasts. 
Intact primary bronchial epithelial cells and intact primary 
bronchial fi broblasts had negligible surface staining (data not 
Figure 4. Specifi city of the monoclonal anti-IL-13Rα2 antibody analyzed 
by fl ow cytometry. A, Primary bronchial epithelial cells were either left 
intact (black line) or permeabilized with saponin (blue line) and stained 
with anti-IL-13Rα2 antibody. The red fi lled histogram shows isotype 
control staining. There is no staining on intact cells, whereas permeabilized 
cells have positive staining. Jurkat cells, either intact (B) or permeabilized 
(C), were stained with a specifi c monoclonal IL-13Rα2 antibody and 
analyzed by fl ow cytometry. Fluorescence intensity is represented by open 
histograms with a black line; red fi lled histograms refer to the background 
staining of isotype-matched controls. There is no staining either on intact 
or in permeabilized Jurkat cells. 
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shown). In contrast, both permeabilized primary bronchial 
epithelial cells and permeabilized primary bronchial fi broblasts 
had a bright uniform granular pattern of cytoplasmic staining 
in both cell types (Figure 5). Analysis of individual confocal 
planes revealed that IL-13Rα2 expression is confi ned to 
the cytoplasm with no nuclear staining in both bronchial 
epithelial cells and bronchial fi broblasts (data not shown). In 
all experiments, use of appropriate isotype-matched control 
antibodies revealed no staining.
Discussion
In this report, we describe the cellular localization of 
IL-13Rα2 in human primary bronchial epithelial cells and 
fi broblasts, as well as the pattern of IL-13Rα2 expression in 
the human bronchial mucosa.
Initial experiments showed that specifi c IL-13Rα2 mRNA 
transcripts are present in primary bronchial epithelial cells, 
primary bronchial fi broblasts, U937 cells, and various airway 
epithelial cell lines, in accordance with previous studies [20-
22]. In addition, weak IL-13Rα2 mRNA expression was 
found in peripheral leukocytes. Flow cytometry showed no 
A B
C D
Figure 5.  Localization of interleukin 13 receptor α2 (IL-13Rα2) in 
permeabilized human primary bronchial epithelial cells and fi broblasts. 
Primary bronchial epithelial cells (A, C) and primary bronchial fi broblasts 
(B, D) were cultured on glass coverslips, fi xed, permeabilized, and stained 
with an anti-IL-13Rα2 antibody (C, D), or an isotype-matched control 
antibody (A, B). Maximal projections of optical sections taken at 1 µm 
intervals by confocal laser scanning microscopy are shown. Specifi c 
cytoplasmic IL-13Rα2 staining is shown in blue (C) or green (D), whereas 
nuclei, counterstained with SYTOX Orange, are shown in red. IL-13Rα2 
has a uniform granular cytoplasmic fl uorescent staining pattern (C, D), 
whereas the specimens incubated with the control antibody show no 
staining (A, B). Representative images from 3 separate experiments are 
shown. Scale bar = 40 µm.
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cell-surface IL-13Rα2 expression in either primary bronchial 
epithelial cells or primary bronchial fi broblasts. This was also 
confi rmed by confocal microscopy, which showed negligible 
surface IL-13Rα2 expression on both cell types. Bernard and 
co-workers [13] found high cell-surface IL-13Rα2 expression 
in unstimulated human glioma cell lines, but not in renal 
carcinoma cell lines, by fl ow cytometry, suggesting that IL-
13Rα2 surface expression varies among different human cell 
types. We found IL-13Rα2 to be an intracellular molecule in 
primary bronchial epithelial cells and fi broblasts, as well as 
various airway epithelial cell lines and U937 cells, in agreement 
with previous studies [20-22]. In vitro expression of IL-13Rα2 
protein in primary bronchial epithelial cells was approximately 
twice that of expression in bronchial fi broblasts when analyzed 
by fl ow cytometry. Similarly, in vivo data showed that bronchial 
epithelial cells are the main site of IL-13Rα2 immunoreactivity 
in the human airways. We demonstrated that intracellular binding 
of the monoclonal anti-IL-13Rα2 antibody used in our studies 
is specifi c, since no IL-13Rα2 protein expression was detected 
in the intracellular compartment of permeabilized Jurkat cells, 
previously shown to lack IL-13Rα2 mRNA expression. 
Confocal microscopy showed that the intracellular pool 
of IL-13Rα2 has a diffuse granular pattern in the cytoplasmic 
compartment of both primary bronchial epithelial cells and 
primary bronchial fi broblasts. To our knowledge, this is the 
fi rst study demonstrating the cellular localization of IL-13Rα2 
in primary bronchial epithelial cells and fi broblasts. Our 
fi ndings are in accordance with those of Daines and Khurana 
Hersey [20], who showed by confocal microscopy that IL-
13Rα2 has a diffuse cytoplasmic distribution in primary human 
epithelial nasal cells and A549 cells. In agreement with their 
study, we also observed some bright localized cytoplasmic 
staining in both bronchial epithelial cells and fi broblasts that 
may represent distinct vesicles containing IL-13Rα2. Although 
the functional role of intracellular IL-13Rα2 has not yet been 
fully elucidated, in a recent in vitro study using U937 cells 
and murine splenocytes stably transfected with Flag-human 
IL-13Rα2, intracellular IL-13Rα2 was shown to serve as a 
reservoir of biologically active soluble IL-13Rα2 [24]. In 
addition, soluble IL-13Rα2 was found in bronchoalveolar 
lavage fl uid from asthmatics and normal controls [25], while 
the intracellular pool of IL-13Rα2 was shown to mobilize to the 
cell surface in response to interferon  and phorbol myristate 
acetate in U937 cells and primary human monocytes [20]. 
In conclusion, we have demonstrated that IL-13Rα2 
is predominantly an intracellular rather than a membrane-
bound protein in human primary bronchial epithelial cells 
and fi broblasts and displays a diffuse granular cytoplasmic 
distribution in both cell types. Furthermore, it is expressed in 
vivo in the human airway mucosa mainly by bronchial epithelial 
cells. Further studies are warranted to determine the functional 
role of intracellular IL-13Rα2 in the human airways.
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